What is the future for cancer clinical trials?

Two important phenomena have been characterized in recent years in the research on new drugs in oncology that will affect the future of cancer clinical trials. On the one hand, remarkable advances have arisen thanks to the conjunction between the deeper understanding of the molecular mechanisms underlying cancer growth and the ability to produce drugs that are directed against them. A few years ago, for example, EGFR mutations were found in non-small-cell lung cancer (NSCLC). These were related to exaggerated response after stimulation with the ligand and to high sensitivity to specific tyrosine kinase inhibitors, such as gefitinib, erlotinib or afatinib [1].

Click here to view the full article